Larimar Therapeutics
LRMR
94 hedge funds and large institutions have $153M invested in Larimar Therapeutics in 2018 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 35 increasing their positions, 30 reducing their positions, and 10 closing their positions.
50% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 10
17% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 30
6% more funds holding
Funds holding: 89 → 94 (+5)
1.11% more ownership
Funds ownership: 5.88% → 7% (+1.1%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
50% less capital invested
Capital invested by funds: $304M → $153M (-$151M)
85% less call options, than puts
Call options by funds: $5K | Put options by funds: $34K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
+$11.5M |
| 2 |
BlackRock
New York
|
+$3.91M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$1.7M |
| 4 |
Morgan Stanley
New York
|
+$1.6M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$1.27M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$3.07M |
| 2 |
Millennium Management
New York
|
-$2.91M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
-$2.9M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.49M |
| 5 |
KC
Kepos Capital
New York
|
-$978K |
LRMR Hedge Fund Activity: Q4 2018 in Review
94 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Larimar Therapeutics (LRMR) for Q4 2018, worth a combined $153M — down 50% from $304M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new LRMR positions and 10 closed out — a net gain of 5 holders — while 35 added to existing stakes and 30 trimmed.
The largest buyer was 683 Capital Management, opening a new position worth an estimated $11.5M. The largest seller was T. Rowe Price Associates, cutting an estimated $3.07M.
- 94 institutional investors held Larimar Therapeutics (LRMR) as of Q4 2018, up from 89 in Q3 2018.
- Funds reported $153M of Larimar Therapeutics stock for Q4 2018, down 50% quarter-over-quarter.
- 15 funds opened new Larimar Therapeutics positions in Q4 2018 and 10 closed out, a net change of +5 holders.
- The largest Larimar Therapeutics buyer in Q4 2018 was 683 Capital Management, an estimated $11.5M added.
- The largest Larimar Therapeutics seller in Q4 2018 was T. Rowe Price Associates, an estimated $3.07M sold.
Based on aggregated 13F filings for Q4 2018.